The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  66 (2024)
Volume  65 (2023)
Volume  64 (2022)
Volume  63 (2021)
Volume  62 (2020)
Volume  61 (2019)
Volume  60 (2018)
Volume  59 (2017)
Volume  58 (2016)
Volume  57 (2015)
Volume  56 (2014)
Volume  55 (2013)
Volume  54 (2012)
Volume  53 (2011)
Volume  52 (2010)
Related articles

VOLUME 62 , ISSUE 1 ( January-March, 2020 ) > List of Articles

EDITORIAL

Are We Moving Towards Development of Universal Drug Regimen for Treatment of Tuberculosis?

Rajendra Prasad, Abhijeet Singh, Nikhil Gupta

Citation Information : Prasad R, Singh A, Gupta N. Are We Moving Towards Development of Universal Drug Regimen for Treatment of Tuberculosis?. Indian J Chest Dis Allied Sci 2020; 62 (1):5-7.

DOI: 10.5005/ijcdas-62-1-5

License: NA

Published Online: 07-03-2020

Copyright Statement:  NA


Abstract
PDF Share
  1. World Health Organization. Global Tuberculosis Report 2019. Geneva: WHO; 2019 (WHO/CDS/TB/2019.15). Available at URL: https://www.who.int/tb/publications/global_report/en/. Accessed on: December 15, 2019.
  2. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's new end TB strategy. Lancet 2015;385:1799–1801.
  3. Revised National Tuberculosis Control Programme. New Delhi, India: RNTCP; 2017. Central TB Division, Ministry of Health and Family Welfare, Government of India. National Strategic Plan for Tuberculosis Elimination 2017-2025. (Draft) Available at URL: http://www.tbcindia.gov.in/WriteReadData/NSP%20Draft%20 20.02.2017%201.pdf. Accessed on: December 16, 2019.
  4. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update (October 2016 revision). (WHO/HTM/TB/2016.04). WHO, Geneva, 2016. Available at URL: https://apps.who.int/iris/bitstre am/10665/250125/1/9789241549639-eng.pdf. Accessed on: December 15, 2019.
  5. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. WHO, Geneva, 2019 (WHO/CDS/TB/2019.7); Available at URL: https://www.who.int/tb/.../consolidated guidelines-drug-resistant-TB-treatment/en/. Accessed on: December 22, 2019.
  6. Khan FA, Hamid Salim MA, du Cros P, Casas EC, Khamraev A, Sikhondze W, et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur Respir J 2017;50:1700061.
  7. Moodley R, Godec TR. Short-course treatment for multidrugresistant tuberculosis: the STREAM trials. Eur Respir Rev 2016; 25:29–35.
  8. Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med 2019;380:1201–13.
  9. Udwadia, ZF, Tornheim, JA, Ganatra S, DeLuca A, Rodrigues CS, Gupta A, et al. Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic. BMC Infect Dis 2019;19:94.
  10. Research Excellence to Stop TB Resistance. Drug-resistant tuberculosis: clinical trials progress report. RESIST TB,
  11. Available at URL: http://resisttb.org/docs/RESIST-TBCTPR_6_6_2018.pdf. Accessed on: June 14, 2019.
  12. Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol 2009;2:215–8.
  13. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med 2020;382:893–902.
  14. D iacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012;380(9846):986–93.
  15. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), andpyrazinamide during the first 8 weeks of anti-tuberculosis treatment: a phase 2b, openlabel, partly randomised trial inpatients with drug-susceptible or drug-resistant pulmonarytuberculosis. Lancet 2015;385:1738–48.
  16. T weed CD, Dawson R, Burger DA, Conradie A, Crook AM, Mendel CM, et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med 2019;7:1048–58.
  17. Wallis R S, Cohen T, Menzies N A, Churchyard G. Pantuberculosis regimens: an argument for. Lancet Respir Med 2018;6:239–40.
  18. D heda K, Gumbo T, Lange C, Horsburgh C R, Furin J. Pantuberculosis regimens: an argument against. Lancet Respir Med 2018;6:240–42.
  19. S hrestha S, Knight GM, Fofana M, Cohen T, White RG, Cobelens F, et al. Drivers and trajectories of resistance to new first-line drug regimens for tuberculosis. Open Forum Infect Dis 2014;1:ofu073.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.